



# Tuesday 2 July 2019

## **PVRI Innovative Drug Development Initiative (IDDI)**

// Held in: Fleurs (located in Les Petits Salons)

**Open session and working lunch**

**13:00 - 15:00**

**Welcome and introduction by the IDDI Chair**

// Paul Corris

**13:00 - 13:10**

**Clinical trial designs and endpoints working group**

// Peter Fernandes & Sylvia Nikkho

**13:10 - 13:40**

Physical activity as measured by actigraphy as a new primary endpoint

- FDA acceptance and feedback for an IPF Clinical Trial
- Change in MVPA as a primary endpoint for Phase 3
- MCID estimation
- Anchoring of Physical Activities to PROs
- Next Steps EU & ROW acceptance as a primary endpoint
- Adaptations to other programmes

Open discussion and debate

# Scientific Programme

## Tuesday 2 July 2019

### **Risk scores**

// Olivier Sitbon, Mardi Gomberg-Maitland & CQ Deng

Pros and Cons of risk scores as potential clinical endpoints

Statistical aspects of incorporating risk scores into clinical trials

Open discussion and debate

**13:40 - 14:10**

### **Repurposing drugs for PH**

// Mark Toshner

Modern Drug Repurposing in PH - What, where and how

- What - Are we happy with our preclinical pipelines for picking drug targets?
- Where - How do investigators and industry create the right environment for repurposing in a mature therapeutic landscape?
- How - Is our classical model for phase 2 trials fit for purpose?

Open discussion and debate

**14:10 - 14:40**

### **Biomarkers**

// Lawrence Zisman

New insights into biomarker development in PH

**14:40 - 14:50**

ADJOURN

